Black Diamond Therapeutics (BDTX) Enterprise Value (2018 - 2026)
Black Diamond Therapeutics' (BDTX) quarterly Enterprise Value came in at -$118.3 million in Q1 2026, up 22.4% YoY from -$96.6 million in Q1 2025, and up 8.08% on a QoQ basis from -$128.7 million in Q4 2025.
Black Diamond Therapeutics (BDTX) Enterprise Value (2018 - 2026) Analysis & Trends
Black Diamond Therapeutics (BDTX) has 9 years of Enterprise Value data on file, last reported at -$118.3 million in Q1 2026.
- Quarterly Enterprise Value rose 22.4% year-over-year to -$118.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$118.3 million (up 22.4% YoY) and the FY2025 annual result came in at -$128.7 million, down 30.51% from the prior year.
- Enterprise Value rose to -$118.3 million in Q1 2026, from -$128.7 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$89.5 million in Q2 2023 to a low of -$179.7 million in Q1 2022.
- A 5-year average of -$129.6 million and a median of -$128.7 million in 2025 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2023 — Enterprise Value surged 44.36% — and 2024, when it tumbled 37.36%.
- Tracing BDTX's Enterprise Value over 5 years: stood at -$122.8 million in 2022, then dropped by 7.0% to -$131.4 million in 2023, then climbed by 24.98% to -$98.6 million in 2024, then slumped by 30.51% to -$128.7 million in 2025, then grew by 8.08% to -$118.3 million in 2026.
- The last three Enterprise Value figures came in at -$118.3 million (Q1 2026), -$128.7 million (Q4 2025), and -$135.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Black Diamond Therapeutics | 125.92 Mn | 15.42 Mn | - | -110.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -110.51 Mn |
| Mar 31, 2026 | -118.26 Mn |
| Dec 31, 2025 | -128.65 Mn |
| Sep 30, 2025 | -135.50 Mn |
| Jun 30, 2025 | -142.83 Mn |
| Mar 31, 2025 | -152.40 Mn |
| Dec 31, 2024 | -98.58 Mn |
| Sep 30, 2024 | -112.68 Mn |
| Jun 30, 2024 | -122.97 Mn |
| Mar 31, 2024 | -115.20 Mn |
| Dec 31, 2023 | -131.40 Mn |
| Sep 30, 2023 | -144.26 Mn |
| Jun 30, 2023 | -89.53 Mn |
| Mar 31, 2023 | -103.37 Mn |
| Dec 31, 2022 | -122.81 Mn |
| Sep 30, 2022 | -144.18 Mn |
| Jun 30, 2022 | -160.89 Mn |
| Mar 31, 2022 | -179.74 Mn |
| Dec 31, 2021 | -209.79 Mn |
| Sep 30, 2021 | -235.01 Mn |